Conference Menu
Pre-Conference Workshop
Overview
Day 1
Day 2
Distinguished Faculty
Register
PDF Download
Hotel & Travel
Sponsor
Press Pass
Request Brochure
Sponsoring Associations:
.jpg "ACRO")
.jpg "Asia Pacific")
.jpg "SABPA_2008")
Sponsoring Organization:
Lead Sponsoring Publications:
.gif "BioITWorld")
.jpg "Science AAAS")
.jpg "The Scientist")
Sponsoring Publications:
.jpg "Asia Monitor")
.jpg "Business Monitor")
.jpg "Bio Outsourcing Asia")
.jpg "Espicom")
.jpg "The Pink Sheet")
.jpg "The Pink Sheet Daily")
.jpg "Pharma Agreement News")
.jpg "PharmAsia News")
.jpg "Pharma_Company_Insight")
.jpg "Pharma Insight")
.jpg "PharmaVoice")
.jpg "Reviews on Recent Clinical Trials")
Web Partners:
.jpg "Biolexis")
.jpg "Pharmalicensing")
.jpg "PharmCast")
.jpg "Pharma China")
|
|
 A New Way to Discover Innovative Medicine: Approach from the East
Li Chen, Ph.D., Chief Scientific Officer, Roche R&D Center (China) Ltd |
 Aligning Business, Corporate, and International Tax Strategy
Rickey Pate, MBA, JD, Director of Global Tax, Eli Lilly and Company
|
 How to Balance Internal and External Resources to Provide DMPK Support for Drug Discovery in China
Ji Zhang, Ph.D., Director, DMPK, GlaxoSmithKline R&D China
|
 Building an Integrated Biomedical Institute for Innovative Medicine in China
Ling Chen, Ph.D., Director General, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences
|
 Drug Discovery R&D in China: From Functional Capacity Outsourcing to Integrative Partnership
Guoxin Zhu, Ph.D., CSO, Eli Lilly Asia, Inc., Shanghai Rep. Office
|
 Accelerate Oncology Clinical Development in Asia
Michael Shi, Ph.D., Director and Biomarker Project Leader, Exploratory Oncology Development, Novartis
|
 The Latest Insights from China into Translational Research for Cancer
Jun Ren, M.D., Ph.D., Clinical Trials Coordination, Peking University School of Oncology/Beijing Cancer Hospital
|
 Strategic Planning for Clinical Development Operations in China: Legal and Regulatory Considerations
Shaoyu Chen, Senior Counsel, Development & Regulatory Law Group, Amgen Inc.
|
Three Days of Interactive Discussions, Case Studies, Break-out Roundtables, and Panels
- In-Licensing, Out-Licensing, and Risk Sharing: The China Landscape for Partnership Deals
- Interactions and Initiatives Taken for Drug Development Between China and the Rest of Asia: A Focus on Oncology
- Opportunities for Drug Discovery in China: Chemistry, Biology, Integrated Projects, & Traditional Chinese Medicine
- How to Conduct High Quality, Cost Effective GLP Safety Studies in China
- Strategic Planning for Clinical Development Operations in China
- Comparative Assessment of Regulatory Processes and Time Lines
- The Role of Academic Clinical Trials Units for Drug Development in Asia
- Business Model Case Studies: Real Challenges and Strategies to Harness R&D Capabilities in China
For questions about this conference, contact:
Micah Lieberman
Conference Director, Pharmaceutical Strategy Series
Cambridge Healthtech Institute
Tel: +1 541.482.4709
E-mail: mlieberman@pharmaseries.com
For partnership and sponsorship opportunities, contact:
Arnold Wolfson
Manager, Business Development
Cambridge Healthtech Institute
Tel: +1 781.972.5431
E-mail: awolfson@healthtech.com
|
|
|